08:56 AM EDT, 03/25/2025 (MT Newswires) -- Cassava Sciences ( SAVA ) said Tuesday that topline results from its phase 3 REFOCUS-ALZ study of simufilam showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease.
The biotech company said the results did not meet the co-primary, secondary, and exploratory biomarker endpoints.
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 76 compared to placebo.
Shares of Cassava Sciences ( SAVA ) were down 18% in recent premarket activity.